UnknownNot Applicable

Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease

United States25 participantsStarted 2023-10-01

Plain-language summary

The goal of this observational study is to learn about the changes in coagulation factor VIII and IX levels in patients undergoing liver transplantation to help guide future management of coagulation factor replacement in patients with hemophilia and liver disease. The question we aim to answer is: should the recommendations for factor replacement in patients with hereditary bleeding disorders be altered in the setting of end stage liver cirrhosis? Participants will be asked to provide two blood samples, one at the beginning of their liver transplant, and one after their liver transplant.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * participants who have end stage liver disease who are listed for liver transplantation and have an accepted organ offer * age \> 18+ * MELD \> 25 Exclusion Criteria: * undergoing multi-organ transplant * tumor MELD exception points * has hereditary coagulation disease * currently on therapeutic blood thinner or anti-platelet medication (ie. aspirin, plavix, warfarin, heparin)

What they're measuring

Factor VIII level

Timeframe: 12 hours

Factor IX level

Timeframe: 12 hours

Thromboelastography (TEG) values

Timeframe: 12 hours

Trial details

NCT IDNCT06014320

SponsorStanford University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-04-01

Contact for this trial

Alexandra Ruan, MD

650-723-4000 aruan@stanford.edu

View on ClinicalTrials.gov More Liver Cirrhosis trials